Name | Last modified | Size | Description | |
---|---|---|---|---|
Parent Directory | - | |||
SmPC-Guidelines_Chec..> | 2023-06-27 10:33 | 523K | ||
Annexure-5-PIL-Revie..> | 2023-06-27 10:20 | 48K | ||
Annexure-4-SmPC-Revi..> | 2023-06-27 10:20 | 41K | ||
NAFDAC-Guidelines-on..> | 2019-06-11 12:29 | 668K | ||
Guidance-document-Ma..> | 2018-09-11 22:29 | 813K | ||
Additional-Strength-..> | 2018-06-18 13:46 | 227K | ||
Bioequivalence-Trial..> | 2018-06-18 13:45 | 254K | ||
Biopharmaceutics-Cla..> | 2018-06-18 13:45 | 236K | ||
Guidelines-for-Label..> | 2018-06-18 13:45 | 330K | ||
Guidelines-for-Patie..> | 2018-06-18 13:44 | 190K | ||
Guidelines-on-Regist..> | 2018-06-18 13:44 | 1.0M | ||
Guidelines-on-Variat..> | 2018-06-18 13:43 | 1.3M | ||
Letter-of-Access-for..> | 2018-06-18 13:43 | 135K | ||
Letter-of-Access-for..> | 2018-06-18 13:42 | 135K | ||
Quality-Information-..> | 2018-06-18 13:42 | 420K | ||
Quality-Overall-Summ..> | 2018-06-18 13:42 | 324K | ||
Summary-of-Product-C..> | 2018-06-18 13:41 | 195K | ||